Complete coding region of the new HLA-DQB1*0612 allele, obtained by RT-PCR

A novel HLA-DQB1 allele was detected by oligotyping in the Bubi population of Equatorial Guinea. In order to characterize the new allelic variant, a RT-PCR method which permitted the cloning of its complete coding region was designed. With this method, we have determined the nucleotide sequence of the new DQB1*0612 allele, related to *0604 and *0609 but differing from them at polymorphic codon 70. A proposal for the improvement of the sequencing strategies of HLA class II alleles is made.     

De novo 13q partial duplication identified by cytogenetic, biochemical and molecular approaches

A 3.5-month-old female infant manifesting dysmorphic facies, developmental delay and failure to thrive was referred for cytogenetic evaluation. Peripheral lymphocytes revealed three chromosomally distinct cell lines: 46,XX/46,XX,10p+/47,XX,10p+,+mar. Dermal fibroblasts revealed only the 46,XX,10p+cell line. High resolution G-, R-, and Q-banding suggested that the extra chromosomal material (10p+) represented a duplication of the segment 13q14----13qter. Parental karyotypes were normal. As absolute identification of de novo chromosomal abnormalities, based solely on cytogenetic studies, is sometimes difficult, both biochemical and molecular approaches were undertaken to elucidate this abnormality in more detail. Dosage effects were examined using esterase D (localized to 13q14.1) and the DNA probes p1E8 and p9A7 (localized to 13q22 and 13q31/32, respectively). These studies suggested the presence of only 2 copies of esterase D, but 3 copies of both DNA probes, allowing identification of the breakpoint at 13q14.2.     

New HLA-A*11 allele,A*1112, identified by sequence-based typing

In this report, we describe the identification of HLA-A*1112, a novel HLA-A*11 allele found in two Italian families. The new allele was detected during routine HLA typing by a polymerase chain reaction sequence-specific primer and was confirmed by high-resolution sequencing-based typing. The nucleotide sequences of HLA-A*1112 exons 2 and 3 are identical to HLA-A*11011 except for a single nucleotide substitution in codon 90 (GAC-->GCC).     

Autosomal recessive acrorenal syndrome

We describe two sibs with tetraectrodactyly and oligomeganephronic renal hypoplasia. The parents were unaffected. This syndrome of apparently autosomal recessive origin appears to be the first Mendelian form of the acrorenal developmental field defect identified so far. © 1992 Wiley-Liss, Inc.     

H1N2新亚型流感病毒神经氨酸酶基因来源的进一步研究

对流感病毒Ｈ１Ｎ２亚型重组株Ａ／哈防／１／８８、Ａ／哈防／１２／９２以及Ｈ３Ｎ２亚型病毒株Ａ／雅防／２／８７、Ａ／京防／５７／８９８和Ａ／粤防／１／９２神经氨酸酶（ＮＡ）基因核苷酸全序列的测定，进一步弄清了Ａ／哈防／１／８８病毒株的ＮＡ基因确来自当时人群中流行的Ｈ３Ｎ２亚型病毒株，很可能是来自Ａ／雅防／２／８７类病毒株；而Ａ／哈防／１２／９２病毒株的ＮＡ基因可能是与Ａ／哈防／１／８８病毒株的ＮＡ基     

两种兔源内毒素结合蛋白的分离、纯化及其体外生物学活性的对比研究

目的　从烧伤合并内毒素血症致多器官损害家兔血清中分离纯化内毒素结合蛋白 ,并初步对比研究它们的生物学活性。方法　兔血清蛋白质通过二步离子交换层析 (Bio Rex 70Resin、Mono Q)及凝胶过滤分离纯化 ,并经流式细胞分析实验、绵羊红细胞凝聚实验、氨基末端氨基酸残基测序等方法鉴定 ,再将所获蛋白质作用于体外培养的人单核细胞 (U937) ,观测其分泌TNFα等细胞因子的生物效应。结果　获得两种具有促进内毒素 (LPS)与外周血单核细胞 (PBMC)结合的蛋白质 ,其中一种相对分子质量为 6 0× 10 4 ,其N端 10个氨基酸序列为TNPGLITRIT ,证实为兔内毒素结合蛋白 (LBP) ;另一种蛋白质相对分子质量为 4 8× 10 4 ,其N端 10个氨基酸序列为GSQGTFTSEE ,与NCBI蛋白质库中的氨基酸序列进行比较 ,未发现相同序列 ,命名为p48。结论　p48与LBP具有相似的生物学功能 ,p48的生物学活性稍弱于LBP。提示体内除LBP外 ,p48也同样起着介导LPS的毒性作用。这可能是近年国外研究中阻断LBP的活性后 ,机体毒性反应并无明显减轻的原因之一。     

A new HLA-B allele, B*1565, identified in three unrelated samples

Anew human leukocyte antigen-B allele, B*1565, has been identified during routine typing of cord blood samples. Subsequently, two individuals from the same family as the first cord blood sample plus two unrelated Australian Bone Marrow Donor Registry samples have been found to carry this novel allele.     

The novel HLA-Cw*1802 allele is associated with B*5703 in the Bubi population from Equatorial Guinea

The HLA-Cw*1801 specificity, a Cw7/Cw4 hybrid allele, has recently been described in association with B*8101 (formerly B"DT"). In this study, the new Cw*1802 variant, differing from Cw*1801 at exon 5. is found associated with B*5703 in Bubi individuals from Equatorial Guinea. Confirmatory complete coding regions of B*5703 and B*3910 are also reported.     

Einsparung von Diclofenac durch B-Vitamine: Ergebnisse einer randomisierten Doppelblindprüfung mit reduzierten Tagesdosierungen von Diclofenac (75 mg Diclofenac versus 75 mg Diclofenac plus B-Vitamine) bei akuten Lendenwirbelsäulensyndromen

Summary Pain syndromes of the lumbar spine are one of the main problems in orthopedic practice. The therapeutic effect of NSAIDs is not subject to doubt in this connection.But considering that the application of NSAIDs is frequently associated with side effects, a reduction of dosage would be to the patient's benefit. Clinical studies have shown that concomitant treatment with vitamins B₁, B₆, B₁₂ and diclofenac leads to a more efficient pain relief than treatment using diclofenac alone and thus provides the possibility of saving NSAIDs.This clinical trial was carried out in order to determine whether these results can also be achieved when a reduced dosage of diclofenac (75 mg daily) is used.123 patients with acute pain syndromes of the lumbar spine were treated with either B-vitamins and diclofenac or diclofenac alone for a maximum of 7 days. There was the option to terminate therapy in the trial after 3–4 days in the case of total pain relief.45 patients could stop the treatment due to remission of symptoms. 30 patients belonged to the combination therapy group, the other 15 took diclofenac alone; this difference is statistically significant (p< 0.05).All parameters concerning pain relief and movement of the vertebral column showed statistically significant differences in favour of the B-vitamin-diclofenac-combination, too.The results document the positive influence of B-vitamins on painful vertebral syndromes and indicate that B-vitamins contribute to saving of NSAIDs by shortening the treatment time and reducing daily NSAID-dosage.